Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsRory Shallis, MD
Assistant Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor Adjunct
Biography
Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital.
He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS.
Dr. Shallis also maintains research interest in epidemiological, outcomes and effectiveness research as it pertains to the hematologic malignancies with a goal of identifying barriers to effective care and ultimately strategies to improve the outcomes of patients with these malignant diseases. Dr. Shallis conducts research with the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale University.
Dr. Shallis has presented his research at multiple regional, national and international meetings and is a member of the National Comprehensive Cancer Network (NCCN) clinical guidelines for MDS and AML panels. He is an author on more than 75 peer-reviewed publications and book chapters, most of which as first author and has served as an ad hoc reviewer for many journals including Leukemia, Haematologica, Blood Advances, Leukemia Research, Leukemia & Lymphoma, Acta Haematologica, Hematology, Therapeutic Advances in Hematology, Expert Review of Hematology, BMC Hematology, eJHaem and Future Oncology among others.
Last Updated on November 17, 2022.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Leukemia & Lymphoma Program
- Medical Oncology and Hematology
Education & Training
- Fellowship
- Yale - New Haven Hospital (2020)
- Internship
- Brown University - Rhode Island Hospital (2017)
- Residency
- Brown University - Rhode Island Hospital (2017)
- MD
- Rutgers University - Robert Wood Johnson Medical School (2014)
- BA
- Rutgers College, Cell Biology & Neuroscience Psychology (2010)
Research
Copy Link
Overview
Medical Research Interests
Epidemiology; Leukemia; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders
ORCID
0000-0002-8542-2944
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rory Shallis's published research.
Publications Timeline
A big-picture view of Rory Shallis's research output by year.
Research Interests
Research topics Rory Shallis is interested in exploring.
Jan Philipp Bewersdorf, MD, FACP
Amer Zeidan, MBBS
Nikolai Podoltsev, MD, PhD
Maximilian Stahl, MD
Lourdes Mendez, MD, PhD
Scott Huntington, MD, MPH, MSc
176Publications
3,014Citations
Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia
Myelodysplastic-Myeloproliferative Diseases
Publications
2025
CO60 Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study
Badar T, Heckman M, Zhang Y, Blumenfeld S, Narra R, Curran E, Kota V, Shallis R, Patel A, Advani A, Palmisiano N, Atallah E, Mims A, Coltoff A, Hunter C, Patel S, DuVall A, Omer Z, Jamy O, Jonas B, Foucar C, Reddick L, Hernandez L, Litzow M. CO60 Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study. Value In Health 2025, 28: s53. DOI: 10.1016/j.jval.2025.09.162.Peer-Reviewed Original ResearchIsavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia
Hunter C, Chou A, Roeder H, Eighmy W, Bewersdorf J, Mendez L, Stahl M, Podoltsev N, Zeidan A, Shallis R. Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia. Leukemia Research 2025, 160: 108144. PMID: 41365214, DOI: 10.1016/j.leukres.2025.108144.Peer-Reviewed Original ResearchAltmetricConceptsInvasive fungal infectionsAcute myeloid leukemiaDrug-drug interactionsSide effect profileOverall survivalTransaminase elevationVisual disturbancesMyeloid leukemiaAntifungal prophylactic agentMedian overall survivalRate of complicationsAssociated with higher ratesAntifungal prophylaxisIsavuconazoleFungal infectionsVoriconazoleRetrospective analysisSide effectsPatientsLeukemiaHigher RatesSurvivalNeutropeniaProphylaxisAzoleEarly discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy
Hunter C, Chetlapalli K, Ito S, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Stahl M, Podoltsev N, Zeidan A, Shallis R, Goshua G. Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy. Blood 2025, 146: 6208. DOI: 10.1182/blood-2025-6208.Peer-Reviewed Original ResearchConceptsEarly discharge programAbsolute neutrophil countLow absolute neutrophil countAcute myeloid leukemiaNext therapyIntensive chemotherapyTraditional cohortDirect costsHospital dischargeMyeloid leukemiaDirect costs of careOutpatient clinical careLonger hospitalInpatient bed usePatient's absolute neutrophil countDays of antimicrobial therapyCohort of consecutive patientsCost of careRed blood cell transfusionProgram cost savingsAssociated with longer hospitalSecond-line therapyBlood cell transfusionKaplan-Meier methodRisk exposure periodClinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis
Bidikian A, Al-Musa A, Hunter C, Mendez L, Podoltsev N, Stahl M, Zeidan A, Shallis R, Bewersdorf J. Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis. Blood 2025, 146: 5160-5160. DOI: 10.1182/blood-2025-5160.Peer-Reviewed Original ResearchConceptsAdvent of all-trans retinoic acidMolecular complete remissionAcute promyelocytic leukemiaEarly mortalityFLT3 mutationsPrognostic impactOverall survivalAcute promyelocytic leukemia treatmentPrognostic rolePlatelet countD-dimerMolecular predictorsIndependent predictorsGenetic abnormalitiesEvaluable ptsImpact of genetic abnormalitiesMultivariate analysisPredictors of inferior OSPredictors of early mortalityImpact of prognostic factorsExcellent long-term outcomePeripheral blast percentageBone marrow biopsyFLT3 mutation statusTumor lysis syndromeImpact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States
Stempel J, Wang R, Shallis R, Mendez L, Bewersdorf J, Stahl M, Zeidan A, Ma X, Podoltsev N. Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States. Blood 2025, 146: 6392-6392. DOI: 10.1182/blood-2025-6392.Peer-Reviewed Original ResearchAltmetricConceptsHistory of thrombosisDiagnosis of DMMetformin non-usersMyeloproliferative neoplasmsMetformin usersThrombotic eventsThrombotic riskPolycythemia veraMetformin useEssential thrombocythemiaOlder ptsSevere DMDiabetes mellitusImpact of metforminNo significant associationDM severityFollow-upPhiladelphia chromosome negative myeloproliferative neoplasmsPre-existing cardiovascular risk factorsHistory of thrombotic eventsNon-usersIncidence rate of thrombosisIncidence of thrombotic eventsDevelopment of myeloproliferative neoplasmsIncidence rateTreatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)
Wang R, Stempel J, Shallis R, Bewersdorf J, Mendez L, Stahl M, Zeidan A, Ma X, Podoltsev N. Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA). Blood 2025, 146: 6393-6393. DOI: 10.1182/blood-2025-6393.Peer-Reviewed Original ResearchConceptsMedian time to initiationChronic myeloid leukemiaTime to initiationMonths of diagnosisRetrospective cohort studyTreatment initiationAssociated with higher likelihoodTKI therapyOlder ptsCML diagnosisFollow-upOlder patientsFirst-generation TKI imatinibChronic myeloid leukemia diagnosisEnd Results Medicare-linked databaseMultivariate Cox proportional hazards modelLow-income subsidySecond-generation TKIsMedicare-linked databaseAge of diagnosisCox proportional hazards modelsPre-GProportional hazards modelGeneric imatinibImatinib usersAcute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study
Gomez-Arteaga A, Shallis R, Nawas M, Guo L, Oloyede T, Ahn K, Bachanova V, Byrne M, Giralt S, Gowda L, Jakubowski A, Litzow M, Milano F, Page K, Saber W, Bejanyan N, Broglie L, Xu X, Yared J. Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study. Blood 2025, 146: 1060. DOI: 10.1182/blood-2025-1060.Peer-Reviewed Original ResearchConceptsAdverse-risk acute myeloid leukaemiaAcute myeloid leukemiaPost-transplant cyclophosphamideTransplant-related mortalityAllo-HCTGroup 1Group 2Group 3TP53 alterationsCell transplantationMyeloid leukemiaIn vivo T-cell depletionAllogeneic hematopoietic stem cell transplantationSecondary acute myeloid leukemiaAllogeneic hematopoietic cell transplantationAssociated with higher relapse riskHematopoietic stem cell transplantationAssociated with worse survivalDiagnosis to transplantKarnofsky score <Associated with poor prognosisT-cell depletionHigher relapse riskStem cell transplantationHematopoietic cell transplantationClinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database
Kewan T, Bewersdorf J, Lanino L, Blaha O, Stempel J, Al Ali N, DeZern A, Sekeres M, Uy G, Urrutia S, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Chandhok N, Logothetis C, Bidikian A, Getz T, Roboz G, Rolles B, Wang E, Harris A, Amaya M, Hawkins H, Ball S, Grenet J, Xie Z, Madanat Y, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski J, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Komrokji R, Stahl M, Della Porta M, Sallman D, Zeidan A. Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database. Blood 2025, 146: 3863-3863. DOI: 10.1182/blood-2025-3863.Peer-Reviewed Original ResearchConceptsComposite complete remissionCleveland Clinic FoundationAllo-HCTHypomethylating agentsHR-MDSMedian OSComplex karyotypeCR rateTP53 mutationsCo-mutationsTreatment responseResponse to HMATreated with hypomethylating agentsHigh-risk myelodysplastic syndromeCopy neutral loss of heterozygositySurvival rateAllogeneic hematopoietic transplantationHypomethylating agent combinationsAssociated with poor outcomesBone marrow blastsRisk myelodysplastic syndromesPost-allo-HCTNegative prognostic factorYear survival rateTP53 wild-typeThe prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome
Rolles B, Bewersdorf J, Kewan T, Blaha O, Stempel J, Lanino L, Al Ali N, DeZern A, Sekeres M, Uy G, Urrutia S, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Chandhok N, Logothetis C, Bidikian A, Getz T, Roboz G, Wang E, Amaya M, Hawkins H, Ball S, Grenet J, Xie Z, Madanat Y, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski J, Sallman D, Enjeti A, Alrabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Della Porta M, Komrokji R, Zeidan A, Stahl M. The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome. Blood 2025, 146: 3865-3865. DOI: 10.1182/blood-2025-3865.Peer-Reviewed Original ResearchConceptsMarrow complete remissionOverall response rateInternational Working Group criteriaComposite CRCount recoveryHematologic improvementAllo-HCTInternational Working GroupMedian OSComplete remissionHR-MDSMedian ageBone marrowClinical trialsAllogeneic stem cell transplantationMedian age of patientsPartial hematologic recoveryStem cell transplantationNon-transplant patientsHypomethylating agent-based therapyKaplan-Meier methodAge of patientsAgent-based therapyLog-rank testRoutine clinical practiceChoice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study
Badar T, Jamy O, Lin C, Patel A, Wang Y, Shallis R, Diebold K, Coltoff A, Goldberg A, Bewersdorf J, Zabel K, Foucar C, Abaza Y, Guru Murthy G, Palmisiano N, Duvall A, Kota V, Patel S, Zeidan A, Atallah E, Litzow M. Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study. Blood 2025, 146: 874-874. DOI: 10.1182/blood-2025-874.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAllo-HCTClinical outcomesMultivariate analysisCR/CRi rateVenetoclax combinationsHypomethylating agentsPropensity score matchingMyeloid leukemiaMatched CohortMedian event free survivalAllogeneic stem cell transplantationTP53-mutant acute myeloid leukemiaResponse rateEvent free survivalMedian Follow-UpStem cell transplantationMulticenter observational studyProportion of ptsInherent chemoresistanceTP53-mFree survivalCount recoveryComplex cytogeneticsOverall survival
Academic Achievements & Community Involvement
Copy Link
Activities
activity National Comprehensive Cancer Network (NCCN) - Myelodysplastic Syndromes Guideline Panel
12/01/2020 - PresentCommitteesMemberactivity Older Adult AML Working Group - National Cancer Institute (NCI) Myeloid Precision Medicine Initiative
09/01/2020 - PresentPeer Review Groups and Grant Study SectionsMemberactivity ECOG-ACRIN Leukemia Committee
07/23/2020 - PresentCommitteesMemberactivity American Society of Hematology (ASH)
07/03/2017 - PresentProfessional OrganizationsMemberactivity American Society of Clinical Oncology (ASCO)
07/03/2017 - PresentProfessional OrganizationsMember
Honors
honor Top Overall Abstract
06/08/2020Regional AwardMyeloid Malignancies SymposiumDetailsUnited Stateshonor Hematology/Oncology Fellowship Program Research Award
06/01/2019Yale School of Medicine AwardYale Cancer CenterDetailsUnited States
News
Copy Link
News
- December 13, 2024Source: OncLive
How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- May 01, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (May 2024)
- March 25, 2024
Yale’s Post ASH Review
Get In Touch
Copy Link